Anthony M Brade1, Frederik Wenz2, Friederike Koppe3, Yolande Lievens4, Belen San Antonio5, Neill A Iscoe6, Anwar Hossain7, Nadia Chouaki8, Suresh Senan9. 1. Radiation Oncology Division, Trillium Health Partners, Mississauga, Ontario, Canada. Electronic address: anthony.brade@thp.ca. 2. Department of Radiation Oncology, University Hospital Mannheim, Mannheim, Germany. 3. Department of Radiation Oncology, Institute Verbeeten, Tilburg, Netherlands. 4. Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium. 5. Lilly España, Madrid, Spain. 6. Eli Lilly Canada, Ontario, Canada; Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. 7. Eli Lilly and Company, Indianapolis, Indiana. 8. Eli Lilly and Company, Neuilly-sur-Seine, France. 9. Department of Radiation Oncology, VU University Medical Center, Amsterdam, Netherlands.
Abstract
PURPOSE: Chemoradiation therapy trials of different tumors, including lung cancer, have shown a correlation between protocol deviations and adverse outcomes. Radiation therapy quality assurance (RTQA) was mandated for all patients treated in the PROCLAIM trial evaluating 2 different chemoradiation therapy regimens. The RTQA results were evaluated from the PROCLAIM study, and the impact of irradiation deviations on efficacy outcomes was investigated. METHODS AND MATERIALS: The study was conducted from 2008 to 2014. Review of the irradiation plan was mandated for all patients. Real-time review was performed prior to irradiation start for the first enrolled patient at each site and randomly in 20% of additional patients, with non-real-time review in the remainder. The RTQA criteria evaluated included planning target volume coverage, dose homogeneity, volume of lung receiving ≥20 Gy, and maximum point dose to spinal cord. RESULTS:Major RTQA violations occurred in 40 of 554 patients, treated at 28 sites. Seven sites treated ≥2 patients with major violations. Stage IIIB disease and larger planning target volume were observed more frequently in patients with major violations. Major violations were more prevalent in sites treating either <6 patients or >15 patients. Patients treated at sites enrolling ≥2 patients with major violations (n = 86) had lower median overall survival (21.1 months vs 29.8 months; hazard ratio, 1.442) and progression-free survival (7.3 months vs 11.3 months; hazard ratio, 1.345) than patients treated at sites without major violations. These findings remained significant for overall survival on multivariate analysis. CONCLUSIONS:Major violations in treatment plans were uncommon in the PROCLAIM study, possibly reflecting mandatory RTQA. The RTQA violations were more frequent in patients requiring more complex chemoradiation therapy plans. Poorer observed outcomes at centers with multiple major violations are hypothesis generating.
RCT Entities:
PURPOSE: Chemoradiation therapy trials of different tumors, including lung cancer, have shown a correlation between protocol deviations and adverse outcomes. Radiation therapy quality assurance (RTQA) was mandated for all patients treated in the PROCLAIM trial evaluating 2 different chemoradiation therapy regimens. The RTQA results were evaluated from the PROCLAIM study, and the impact of irradiation deviations on efficacy outcomes was investigated. METHODS AND MATERIALS: The study was conducted from 2008 to 2014. Review of the irradiation plan was mandated for all patients. Real-time review was performed prior to irradiation start for the first enrolled patient at each site and randomly in 20% of additional patients, with non-real-time review in the remainder. The RTQA criteria evaluated included planning target volume coverage, dose homogeneity, volume of lung receiving ≥20 Gy, and maximum point dose to spinal cord. RESULTS: Major RTQA violations occurred in 40 of 554 patients, treated at 28 sites. Seven sites treated ≥2 patients with major violations. Stage IIIB disease and larger planning target volume were observed more frequently in patients with major violations. Major violations were more prevalent in sites treating either <6 patients or >15 patients. Patients treated at sites enrolling ≥2 patients with major violations (n = 86) had lower median overall survival (21.1 months vs 29.8 months; hazard ratio, 1.442) and progression-free survival (7.3 months vs 11.3 months; hazard ratio, 1.345) than patients treated at sites without major violations. These findings remained significant for overall survival on multivariate analysis. CONCLUSIONS: Major violations in treatment plans were uncommon in the PROCLAIM study, possibly reflecting mandatory RTQA. The RTQA violations were more frequent in patients requiring more complex chemoradiation therapy plans. Poorer observed outcomes at centers with multiple major violations are hypothesis generating.
Authors: Elizabeth Huynh; Ahmed Hosny; Christian Guthier; Danielle S Bitterman; Steven F Petit; Daphne A Haas-Kogan; Benjamin Kann; Hugo J W L Aerts; Raymond H Mak Journal: Nat Rev Clin Oncol Date: 2020-08-25 Impact factor: 66.675
Authors: Kelsey L Corrigan; Stephen Kry; Rebecca M Howell; Ramez Kouzy; Joseph Abi Jaoude; Roshal R Patel; Anuja Jhingran; Cullen Taniguchi; Albert C Koong; Mary Fran McAleer; Paige Nitsch; Claus Rödel; Emmanouil Fokas; Bruce D Minsky; Prajnan Das; C David Fuller; Ethan B Ludmir Journal: Radiother Oncol Date: 2021-11-25 Impact factor: 6.280
Authors: Isabel F Remmerts de Vries; Merle I Ronden; Idris Bahce; Femke O B Spoelstra; Patricia F De Haan; Cornelis J A Haasbeek; Birgit I Lissenberg-Witte; Ben J Slotman; Max Dahele; Wilko F A R Verbakel Journal: Cancers (Basel) Date: 2021-11-25 Impact factor: 6.639